IndraLab
Statements
reach
"Herein, we report one critical target of USP3, SMARCA5 and the specific mechanism of USP3-mediated deubiquitination of SMARCA5 in Docetaxel-inducing DNA damage, suggesting that USP3 may be a promising target for anticancer therapy in prostate cancer.SMARCA5, the SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5, was required for DNA-templated events including transcription, DNA replication, and DNA repair [17, 18]."